Thomas Yau

Summary

Affiliation: The Chinese University of Hong Kong

Publications

  1. pmc Metastatic pancreatic cancer: are we making progress in treatment?
    Joanne Chiu
    University Department of Medicine, Queen Mary Hospital, Hong Kong
    Gastroenterol Res Pract 2012:898931. 2012
  2. ncbi Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis
    Joanne Chiu
    University Department of Medicine, Queen Mary Hospital, Hong Kong, China E mail
    Asian Pac J Cancer Prev 14:6585-90. 2013
  3. pmc Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
    Thomas Yau
    Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2 F New Clinical Building, 102 Pokfulam Road, Hong Kong, China
    Invest New Drugs 30:2384-90. 2012
  4. doi Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies
    T Yau
    Department of Medicine, Queen Mary Hospital, Hong Kong, China
    Aliment Pharmacol Ther 27:997-1005. 2008
  5. ncbi A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO)
    Thomas Yau
    Division of Haematology Oncology, University Department of Medicine, Room 405, Professorial Block, Queen Mary Hospital, Pokfulam Rd, Pokfulam, Hong Kong
    Cancer Chemother Pharmacol 61:717-20. 2008
  6. doi Transient carcinoembryonic antigen elevations during adjuvant chemotherapy for colorectal cancer reflect the burden of residual micrometastatic disease
    Thomas Yau
    Division of Haematology Oncology, University Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong
    Clin Colorectal Cancer 9:108-12. 2010
  7. doi Management of advanced hepatocellular carcinoma in the era of targeted therapy
    Thomas Yau
    University Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong
    Liver Int 29:10-7. 2009
  8. ncbi Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
    Thomas Yau
    Breast Unit, Royal Marsden Hospital, Surrey SM2 5PT, UK
    Acta Oncol 45:196-201. 2006
  9. pmc Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease course
    Thomas Yau
    University Department of Surgery, Queen Mary Hospital, University of Hong Kong, Hong Kong
    World J Surg Oncol 6:42. 2008
  10. doi The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits
    Joanne Chiu
    Department of Medicine, Queen Mary Hospital, Hong Kong, China
    Cancer 118:5293-301. 2012

Collaborators

Detail Information

Publications35

  1. pmc Metastatic pancreatic cancer: are we making progress in treatment?
    Joanne Chiu
    University Department of Medicine, Queen Mary Hospital, Hong Kong
    Gastroenterol Res Pract 2012:898931. 2012
    ..The effort in development of targeted therapy in APC continues. This paper summarized key findings in the development of chemotherapy and targeted therapy for APC patients and discussed future directions in management...
  2. ncbi Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis
    Joanne Chiu
    University Department of Medicine, Queen Mary Hospital, Hong Kong, China E mail
    Asian Pac J Cancer Prev 14:6585-90. 2013
    ..Moreover, uncertainties persist as to whether pharmacogenetic differences in Asian populations preclude equally tolerable and effective administration of these drugs...
  3. pmc Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
    Thomas Yau
    Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2 F New Clinical Building, 102 Pokfulam Road, Hong Kong, China
    Invest New Drugs 30:2384-90. 2012
    ..We aimed to evaluate the efficacy and safety of using combination of B + E in treating advanced HCC patients who had failed prior sorafenib treatment...
  4. doi Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies
    T Yau
    Department of Medicine, Queen Mary Hospital, Hong Kong, China
    Aliment Pharmacol Ther 27:997-1005. 2008
    ..Combined use of such drugs enhances tumour response rates, but controlled data quantifying the relative efficacy and cost-effectiveness of different drug combinations on overall survival remain scarce...
  5. ncbi A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO)
    Thomas Yau
    Division of Haematology Oncology, University Department of Medicine, Room 405, Professorial Block, Queen Mary Hospital, Pokfulam Rd, Pokfulam, Hong Kong
    Cancer Chemother Pharmacol 61:717-20. 2008
    ....
  6. doi Transient carcinoembryonic antigen elevations during adjuvant chemotherapy for colorectal cancer reflect the burden of residual micrometastatic disease
    Thomas Yau
    Division of Haematology Oncology, University Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong
    Clin Colorectal Cancer 9:108-12. 2010
    ..Although CEA levels have been reported to rise during adjuvant drug therapies, the mechanism of such 'surges' is not clear. This study was conducted to clarify the clinical significance of this phenomenon...
  7. doi Management of advanced hepatocellular carcinoma in the era of targeted therapy
    Thomas Yau
    University Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong
    Liver Int 29:10-7. 2009
    ..Future progress seems likely to depend on using controlled clinical trials to optimize synergistic combination treatments...
  8. ncbi Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
    Thomas Yau
    Breast Unit, Royal Marsden Hospital, Surrey SM2 5PT, UK
    Acta Oncol 45:196-201. 2006
    ..This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort...
  9. pmc Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease course
    Thomas Yau
    University Department of Surgery, Queen Mary Hospital, University of Hong Kong, Hong Kong
    World J Surg Oncol 6:42. 2008
    ..In general, the prognosis of HCC patients with extra-hepatic metastasis is poor. The most common sites of extra-hepatic metastasis are the lung, abdominal lymph nodes and bone...
  10. doi The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits
    Joanne Chiu
    Department of Medicine, Queen Mary Hospital, Hong Kong, China
    Cancer 118:5293-301. 2012
    ..This study explored the efficacy, tolerability, and survival benefits of using sorafenib in patients with Child-Pugh class B (CPB) cirrhosis...
  11. doi Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib
    Thomas Yau
    The University of Hong Kong, Queen Mary Hospital, Department of Medicine, Hong Kong
    Expert Opin Pharmacother 11:2187-98. 2010
    ..With the recent advances in the knowledge of molecular biology of hepatocellular carcinoma (HCC), there have been encouraging developments in targeted therapy for advanced HCC...
  12. pmc The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib
    Thomas Yau
    Department of Surgery, Queen Mary Hospital, Hong Kong, China
    Oncologist 16:1270-9. 2011
    ..he role of serum alpha-fetoprotein (AFP) changes in predicting the treatment outcomes of advanced hepatocellular carcinoma (HCC) patients to sorafenib remains unknown...
  13. doi Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response
    Thomas Yau
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Cancer 115:428-36. 2009
    ..The current study was a phase 2 open-label study to evaluate the efficacy and tolerability of single-agent sorafenib in the treatment of advanced HCC patients in a hepatitis B-endemic Asian population...
  14. pmc The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC)
    Hilda Wong
    Department of Medicine, Queen Mary Hospital, Hong Kong
    Oncologist 16:1721-8. 2011
    ..We aimed to evaluate and compare the efficacy and tolerability of single-agent sorafenib in treating elderly patients with advanced HCC versus the younger population...
  15. doi Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma
    Thomas Yau
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Cancer 116:5022-9. 2010
    ..This phase 1-2 trial assessed the efficacy and tolerability of an oral angiogenesis inhibitor-PTK787/ZK222584 (PTK)-in combination with intravenous doxorubicin for the treatment of advanced hepatocellular carcinoma (HCC) patients...
  16. pmc Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?
    Hilda Wong
    Department of Medicine, Division of Hematology and Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    Ann Surg Oncol 19:3479-85. 2012
    ..Only limited data on Tg kinetics have been reported to date. Here we aim to evaluate the prognostic and predictive significance of nonstimulated serum Tg velocity (TgV)...
  17. doi The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization
    Thomas Yau
    Department of Medicine, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China
    Cancer 115:5507-15. 2009
    ..The authors evaluated and compared the treatment outcomes of transarterial chemoembolization (TACE) between young (<or=70 years) and elderly (>70 years) patients at their institute over an 18-year period...
  18. pmc Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer
    Hilda Wong
    Division of Hematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Oncologist 16:1535-46. 2011
    ..The identification of predictive biomarkers is of paramount importance to optimize health economic costs and enhance stratification of anti-HER-2 targeted therapies...
  19. doi The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
    Wing L Ho
    Department of Ophthalmology, Caritas Medical Centre, Hong KongDivision of Haematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, Hong Kong
    Acta Ophthalmol 91:604-9. 2013
    ..In conclusion, ocular effects of targeted agents are not uncommon in cancer patients receiving targeted therapy. Ophthalmologists should have high indexes of suspicion to diagnose and treat these complications promptly. ..
  20. pmc Long term survival analysis of hepatectomy for neuroendocrine tumour liver metastases
    Tan To Cheung
    Department of Surgery, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong
    ScientificWorldJournal 2014:524045. 2014
    ..In this study we aim to investigate the outcome of liver resection in neuroendocrine tumour liver metastases (NELM)...
  21. doi Outcome of laparoscopic versus open hepatectomy for colorectal liver metastases
    Tan To Cheung
    Department of Surgery, The University of Hong Kong, Hong Kong, China
    ANZ J Surg 83:847-52. 2013
    ..The aim of this study is to compare the survival outcome of laparoscopic liver resection with open liver resection for colorectal metastases...
  22. doi A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials
    Thomas Yau
    Department of Medicine University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China
    Cancer 113:2742-51. 2008
    ..In this study, the authors constructed a new prognostic score system, the Advanced Liver Cancer Prognostic System (ALCPS), which can objectively predict the probability of 3-month survival...
  23. pmc A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
    Thomas Yau
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China
    Invest New Drugs 31:99-107. 2013
    ..The current study evaluated safety, pharmacokinetics (PK)/ pharmacodynamics (PD) parameters, and potential anti-tumor activity of pegylated recombinant human arginase 1 (peg-rhArg1) in advanced HCC patients...
  24. ncbi Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma
    Thomas Yau
    Department of Surgery and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong
    Gastroenterology 146:1691-700.e3. 2014
    ..We aimed to develop a prognostic classification scheme with treatment guidance for Asian patients with hepatocellular carcinoma (HCC)...
  25. ncbi Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma
    Thomas Yau
    Department of Medicine, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong, China
    Oncology 72:67-71. 2007
    ..Thalidomide is an anti-neoplastic agent with anti-angiogenic and other mechanisms of action. We aim to evaluate the efficacy and toxicity of low-dose (100 mg) thalidomide as the first-line treatment of advanced HCC...
  26. ncbi Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy
    Roland Leung
    Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China
    Anticancer Agents Med Chem 13:382-8. 2013
    ..Thus, the development of potential predictive and prognostic biomarkers to tailor various molecular therapies to different NETs populations is a major unmet need...
  27. doi Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
    Thomas Yau
    Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Clin Cancer Res 17:6914-23. 2011
    ..A phase I dose-escalating study of pazopanib was conducted to determine the maximum tolerated dose (MTD), pharmacokinetic/pharmacodynamic relationships, and clinical activity in patients with advanced hepatocellular carcinoma (HCC)...
  28. pmc PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success
    Hilda Wong
    Division of Hematology Oncology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong
    Pathol Oncol Res 16:87-91. 2010
    ..We propose diagnostic criteria for this under-recognized new clinical syndrome, and recommend that physicians routinely measure serum gastrin levels in persistent cases of PPI-dependent dyspepsia unassociated with H. pylori...
  29. doi 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective
    Tan To Cheung
    Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    J Nucl Med 54:192-200. 2013
    ..We aimed to compare dual-tracer ((11)C-acetate and (18)F-FDG) PET/CT with contrast CT for patient selection on the basis of the Milan criteria...
  30. doi Complications of traditional Chinese/herbal medicines (TCM)--a guide for perplexed oncologists and other cancer caregivers
    Joanne Chiu
    Division of Hematology Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Rd, Pokfulam, Hong Kong
    Support Care Cancer 17:231-40. 2009
    ..If unrecognized, these problems may be misattributed to conventional treatment toxicity or disease progression, and remedial action may be inappropriate or delayed...
  31. pmc Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
    Hilda Wong
    Division of Hematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, Hong Kong
    Oncologist 17:346-58. 2012
    ..Gastric cancer is one of the leading causes of cancer death. With greater understanding of the molecular basis of carcinogenesis, targeted agents have led to a modest improvement in the outcome of advanced gastric cancer (AGC) patients...
  32. ncbi Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy
    Thomas Yau
    Department of Medicine, University of Hong Kong Medical Centre, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China
    Ann Surg Oncol 15:2500-5. 2008
    ....
  33. pmc Colon cancer in a patient with underlying aplastic anemia: A clinical challenge
    Hilda Wong
    Hilda Wong, Thomas Yau, Department of Medicine, Queen Mary Hospital, Hong Kong, China
    World J Clin Oncol 3:29-31. 2012
    ..A high index of suspicion and multidisciplinary input are essential...
  34. ncbi Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma
    Darrell R Borger
    Authors Affiliations Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston Agios Pharmaceuticals, Cambridge, Massachusetts and Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Clin Cancer Res 20:1884-90. 2014
    ....
  35. pmc Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?
    Hilda Wong
    Division of Hematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, Hong Kong
    Therap Adv Gastroenterol 6:15-31. 2013
    ..Further studies are necessary to confirm the suggestion that such classification may predict tumor biology and facilitate selection of an enriched patient population for targeted agents in future studies and in the clinic...